Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701669 | 0.85 | RIPK1 (0.45) | NPC1HTTRAB9ACDK8LMNA | |
| SCHEMBL13701680 | 0.84 | KCNQ3 (0.48) | NPC1HTTRAB9ACDK8LMNA | |
| SCHEMBL13701640 | 0.82 | MEN1 (0.60) | — | |
| SCHEMBL13702390 | 0.82 | CDK8 (0.61) | BLKBTKCDK8DYRK1AULK1 | |
| SCHEMBL13702140 | 0.82 | ERN1 (0.55) | BLKBTKDYRK1A | |
| SCHEMBL22801121 | 0.80 | MAP4K4 (0.57) | BLKBTKCDK8 | |
| SCHEMBL13701676 | 0.80 | GAA (0.44) | CDK8LMNARIPK1DYRK1A | |
| SCHEMBL13611934 | 0.80 | KMO (0.61) | RIPK1DYRK1A | |
| SCHEMBL4257073 | 0.80 | CDK8 (0.59) | NPC1RAB9ACDK8 | |
| SCHEMBL4254452 | 0.79 | KMO (0.59) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | NPC1 1477/4885HTT 3678/4885RAB9A 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.